Epicardial Application of Hydrogel with Amiodarone for Prevention of Postoperative Atrial Fibrillation in Patients After Coronary Artery Bypass Grafting

J Cardiovasc Transl Res. 2020 Apr;13(2):191-198. doi: 10.1007/s12265-019-09905-1. Epub 2019 Jul 31.

Abstract

The objective of this study was to assess the safety and efficacy of local epicardial application of amiodarone-releasing hydrogel for prevention of postoperative atrial fibrillation (POAF) in patients after coronary artery bypass grafting. Patients were randomized into two groups: with the application of amiodarone-releasing hydrogel and the control group. It included 60 patients (47 males, 13 females) (mean age of 62 ± 8.5). POAF incidence differences were statistically significant between two groups: in the study group, the POAF incidence was 3.3%, while in the control group, the POAF incidence was 37% (p < 0.001). Statistically significant differences were revealed in the PQ interval duration. The risk of POAF incidence was calculated using the Cox regression model: the age and the application of amiodarone-releasing hydrogel application were statistically significant. Hospital length of stay in two groups was also different (р < 0.001). The age and the application of amiodarone-releasing hydrogel were statistically significant for POAF incidence.

Keywords: Amiodarone-releasing hydrogel; Clinical study; Coronary artery bypass surgery; Postoperative atrial fibrillation; Prevention.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Aged
  • Amiodarone / administration & dosage*
  • Amiodarone / adverse effects
  • Anti-Arrhythmia Agents / administration & dosage*
  • Anti-Arrhythmia Agents / adverse effects
  • Atrial Fibrillation / diagnosis
  • Atrial Fibrillation / epidemiology
  • Atrial Fibrillation / physiopathology
  • Atrial Fibrillation / prevention & control*
  • Coronary Artery Bypass / adverse effects*
  • Female
  • Heart Rate / drug effects*
  • Humans
  • Hydrogels
  • Incidence
  • Male
  • Middle Aged
  • Pericardium
  • Prospective Studies
  • Risk Assessment
  • Risk Factors
  • Russia / epidemiology
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Arrhythmia Agents
  • Hydrogels
  • Amiodarone